Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Comparative Study of Two Vaccination Schedules for the Subunit Herpes Zoster Vaccine in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disease Patients Treated With Anti-CD20 Therapy: an Open-label Randomised Controlled Trial (TACTIC)

7 september 2026 uppdaterad av: University Hospital, Toulouse

Immunocompromised individuals, such as patients with multiple sclerosis (MS) or diseases of the neuromyelitis optica spectrum (NMOSD) treated with an anti-CD20 monoclonal antibody, present an increased risk of shingles. The immunogenicity - and therefore the clinical effectiveness - of the recombinant vaccine against the varicella zoster virus based on glycoprotein E, recently recommended according to two-dose schedule two months apart in immunocompromised patients aged ≥ 18 years, could be significantly decreased when administered one month before and one month after the infusion of anti-CD20.

We hypothesize that, in patients with MS or NMOSD treated with anti-CD20 administered every six months, a two-dose M0-M6 vaccination schedule consisting of deferring the second dose six months after the first infusion, that is, five months after the anti-CD20 infusion, could improve vaccine immunogenicity and, consequently, the effectiveness of the vaccine.

Studieöversikt

Status

Har inte rekryterat ännu

Betingelser

Intervention / Behandling

Detaljerad beskrivning

Shingles, caused by reactivation of varicella zoster virus (VZV), is a common condition in immunocompromised people. Its prevention, which has long remained a medical need unmet among these patients, was improved thanks to the availability of the recombinant glycoprotein-based VZV vaccine E (gE). Based on demonstrated clinical efficacy and safety profile in the general population as well as in immunocompromised patients, this vaccine is recommended in France according to a two-person schedule doses spaced two months apart in immunocompromised patients aged ≥ 18 years. However, further studies are needed in order to optimize vaccination strategies according to the different types of immunosuppression.

Patients with MS or NMOSD, who are at increased risk of herpes zoster, are extensively treated with anti-CD20 monoclonal antibodies, which are known to significantly alter immune responses to vaccines, in particular when vaccination is carried out early after the infusion of anti-CD20.

We hypothesize that in patients with MS or NMOSD treated with anti-CD20 administered every six months, a two-dose M0-M6 vaccination schedule, consisting of deferring the second dose to six months after the first, that is, five months after the anti-CD20 infusion, could improve vaccine immunogenicity and, consequently, the effectiveness of the vaccine.

In this phase IV randomized, controlled, open-label, parallel-group trial, we will compare, within a homogeneous population of patients with MS or NMOSD receiving antiCD20, the humoral response induced by a two-dose vaccination schedule administered at 2 months (M0-M2, "2-month" or standard group) or 6 months (M0-M6, "6-month" or experimental group). After the screening and inclusion phase, patients randomized to the M0-M2 (standard) and M0-M6 (experimental) groups will receive a first dose of recombinant herpes zoster vaccine (RZV) one month before the next scheduled infusion of anti-CD20 monoclonal antibodies (M1). The second dose of RZV will be given at either 2 months ("2-month group", M2) or 6 months ("6-month group", M6). Patients will receive their usual anti-CD20 monoclonal antibody infusions at the appropriate time M1, M7 and M13. The primary outcome will be evaluated one month after the second vaccine dose (M3 for the "2 months" group and M7 for the "6 months" group). The kinetics, intensity, and persistence of humoral and cellular immune responses, as well as safety, will be analyzed as criteria for secondary judgments during the scheduled follow-up visits until M13.

Studietyp

Interventionell

Inskrivning (Beräknad)

160

Fas

  • Fas 4

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

  • Frankrike
      • Besançon, Frankrike, 25 000
        • Jean Minjoz University Hospital
        • Huvudutredare:
          • Eric Berger, MD
        • Kontakt:
      • Bordeaux, Frankrike, 33 000
        • Pellegrin Hospital Group
        • Kontakt:
        • Huvudutredare:
          • Aurélie Ruet, PHD
      • Caen, Frankrike, 14 033
        • Côte de Nacre University Hospital
        • Kontakt:
        • Huvudutredare:
          • Pierre Branger, MD
      • Clermont-Ferrand, Frankrike, 63 000
        • Gabriel Montpied Hospital
        • Kontakt:
        • Huvudutredare:
          • Pierre Clavelou, MD
      • Créteil, Frankrike, 94 000
      • Dijon, Frankrike, 21 000
        • Dijon Hospital University
        • Kontakt:
        • Huvudutredare:
          • Thibault Moreau, PHD
      • Grenoble, Frankrike, 38 700
        • Nord Hospital - Grenoble University Hospital
        • Huvudutredare:
          • Olivier Casez, MD
        • Kontakt:
      • Libourne, Frankrike, 33 500
        • Libourne Hospital Center
        • Kontakt:
        • Huvudutredare:
          • Arnaud Gagnol, MD
      • Lille, Frankrike, 59 037
        • Roger Salengro Hospital - Lille University Hospital
        • Kontakt:
        • Huvudutredare:
          • Hélène Zephir, PHD
      • Lille, Frankrike, 59 400
        • Catholics Institut Hospitals Group
        • Kontakt:
        • Huvudutredare:
          • Arnaud Kwiatkowski, PHD
      • Lyon, Frankrike, 69 002
        • Lyon Civil Hospices
        • Kontakt:
        • Huvudutredare:
          • Sandra Vukusic, PHD
      • Montpellier, Frankrike, 34 295
        • Gui de Chauliac Hospital - Montpellier University Hospital
        • Kontakt:
        • Huvudutredare:
          • Xavier Ayrignac, PHD
      • Nantes, Frankrike, 44 800
      • Nice, Frankrike, 06 000
        • Pasteur Hospital
        • Kontakt:
        • Huvudutredare:
          • Mikael Cohen, PHD
      • Nîmes, Frankrike, 30 900
        • Nîmes University Hospital
        • Kontakt:
        • Huvudutredare:
          • Eric Thouvenot, PHD
      • Paris, Frankrike, 75 012
        • 15/20 Hospital
        • Kontakt:
        • Huvudutredare:
          • Dalia Dimitri-Boulos, MD
      • Paris, Frankrike, 75 013
        • Pitié Salpetrière Hospital
        • Kontakt:
        • Huvudutredare:
          • Céline Louapre, PHD
      • Paris, Frankrike, 75 019
        • Adolphe de Rothschild Hospital
        • Huvudutredare:
          • Marine Boudot de La Motte, MD
        • Kontakt:
      • Poissy, Frankrike, 78 300
        • Intercommunal Hospital Center of Poissy Saint-Germain
        • Huvudutredare:
          • Olivier Heinzlef, MD
        • Kontakt:
      • Poitiers, Frankrike, 86 000
        • La Miletrie University Hospital
        • Kontakt:
        • Huvudutredare:
          • Amélie Dos Santos, MD
      • Rennes, Frankrike, 35 000
        • Pontchaillou Hospital
        • Kontakt:
        • Huvudutredare:
          • Laure Michel, PHD
      • Rouen, Frankrike, 76 000
        • Charles Nicolle Hospital
        • Kontakt:
        • Huvudutredare:
          • Maxime Guillaume, MD
      • Toulouse, Frankrike, 31 300
        • Purpan Hospital
        • Huvudutredare:
          • Jonathan Ciron, MD
        • Kontakt:
      • Tours, Frankrike, 37 000
        • Tours Hospital University
        • Huvudutredare:
          • Inès Doghri, MD
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Patients with Multiple Sclerosis (any clinical form) or Neuromyelitis optica spectrum disease seropositive for aquaporin-4 antibodies (AQP4+)
  • Aged 18 years or more
  • Treated with anti-CD20 mAbs (Rituximab IV or Ocrelizumab IV or SC) since < 2 years with dosing intervals of 6 months (and for Rituximab, treated with 1g per infusion)
  • Planned to receive the same anti-CD20 mAbs with dosing intervals of 6 months during the 13 months of the study (and for Rituximab, planned to receive 1g per infusion)
  • Known history in the medical file of varicella, or VZV IgG serology known to evidence a prior infection
  • Affiliated or beneficiary of a social security scheme
  • Written and informed consent
  • Understands and agrees to comply with the study procedures

Exclusion Criteria:

  • Temporary contraindication to vaccination (concurrent episode of acute fever >38.5°C)
  • Shingles in the last 12 months or VZV vaccination in the last 5 years
  • Patients already treated or supposed to be treated with Ofatumumab (another anti-CD20 mAbs but delivered with a monthly subcutaneous injection)
  • Patients who received high dose corticosteroids (methylprednisolone at a dose of ≥ 500 mg, administered over 1 to 5 days) in the 3 months prior to inclusion
  • Patients who have been exposed to Cladribine in the prior 12 months
  • Patients who received or were scheduled to receive any vaccination, except for influenza and SARS-CoV-2 vaccines during the epidemic season, within 2 weeks prior to the 2 RZV injections and up to 4 weeks after the second RZV injection
  • Hypersensitivity to the active substance or to one of the excipients
  • Patient protected by the law (guardianship, curatorship)
  • Pregnancy or breast-feeding
  • Women of childbearing potential (WOCBP) without effective contraception throughout the duration of the trial
  • Criteria related to the use of ancillary anti-CD20 treatments (Rituximab and Ocrelizumab):

Hypersensitivity to the active substance or to any of the excipients Severe, active infections Severe immunodeficiency Severe heart failure or severe uncontrolled heart disease Known progressive malignancies

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: 2 months arm
Patients will receive the standard vaccination schedule in two doses in 2 months.
Biologisk: Two-dose M0-M2 vaccination schedule

Patients randomized to the "2 months" vaccination group will receive their first dose of RZV vaccine one month before the next scheduled infusion anti-CD20 monoclonal antibody (M0 corresponding to the visit during the first dose of vaccine, M1 at the time of scheduled anti-CD20 infusion).

The second dose of RZV vaccine will be administered 2 months later. Patients will receive their regular anti-CD20 infusions at times M1, M7, and M13.
Experimentell: 6 months arm
Patients will receive a vaccination schedule in two doses in 6 months.
Biologisk: Two-dose M0-M6 vaccination schedule

Patients randomized to the "6 months" vaccination group will receive their first dose of RZV vaccine one month before the next scheduled infusion anti-CD20 monoclonal antibody (M0 corresponding to the visit during the first dose of vaccine, M1 at the time of scheduled anti-CD20 infusion).

The second dose of RZV vaccine will be administered 6 months later. Patients will receive their regular anti-CD20 infusions at times M1, M7, and M13.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Humoral vaccine response rate for IgG anti-VZV gE response
Tidsram: 3 months for the " 2 months " group and 7 months for the " 6 months " group
It will be defined as the proportion of patients with at least a 4-fold increase in anti-VZV gE antibody titers (measured by ELISA) at 1 month after the 2nd vaccine dose compared to baseline (M0), or seroconversion for those who were seronegative at M0.
3 months for the " 2 months " group and 7 months for the " 6 months " group

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
The humoral response in terms of Geometric Mean Titer (GMT) at 1 month after the 2nd vaccine dose.
Tidsram: 3 months for the " 2 months " group and 7 months for the " 6 months " group

It will be assessed by the ratio (M0-M6 versus M0-M2 groups) of the adjusted Geometric Mean Titer (GMT) of anti-VZV gE IgG at 1 month after the 2nd vaccine dose.

The adjusted GMT will correspond to the GMT at 1 month after the 2nd vaccine dose conditionally to the means of the log transformed GMT before vaccination at baseline (M0) calculated across the treatment groups.
3 months for the " 2 months " group and 7 months for the " 6 months " group
Composite criteria of the humoral response up to M13
Tidsram: 13 months
The kinetics, intensity and persistance will be assessed by the Geometric Mean Titer (GMT) of anti-VZV gE IgG measured at baseline (M0) and up to M13: before the 2nd vaccine dose, 1 month after the 2nd vaccine dose, and prior to the next anti CD20 infusions at M7 and M13.
13 months
Composite criteria of the cellular response at 1 month after the 2nd vaccine dose
Tidsram: 3 months for the " 2 months " group and 7 months for the " 6 months " group

It will be assessed by the cellular vaccine response rate for gE-specific CD4[AIM+] T response measured 1 month after the 2nd vaccine dose.

The cellular VRR is defined as the proportion of patients with a proportion of gE-specific CD4[AIM+] T cells at least 2 times above the cutoff after vaccination.

The proportion of gE-specific CD4[AIM+] T cells among CD4 T cells is defined by the proportion of CD4 T cells expressing at least one Activation-Induced Marker (AIM), as detected by flow cytometry, following in vitro stimulation with a peptide pool covering the entire ectodomain of gE. The AIM include CD69, CD25, OX40, CD40L, and CD137. We will determine the cut-off of gE-specific CD4[AIM+] T cells by assessing cellular immune responses across a range of non-vaccinated, healthy individuals.
3 months for the " 2 months " group and 7 months for the " 6 months " group
Composite criteria of the cellular response at M13
Tidsram: 13 months
The kinetics, intensity and persistance of the cellular response up to M13 will be assessed by the proportion of gE-specific CD4[AIM+] T cells among CD4 T cells measured at baseline (M0) and up to M13 : before the 2nd vaccine dose, 1 month after the 2nd vaccine dose, and prior to the next anti-CD20 infusions at M7 and M13.
13 months
The vaccine safety
Tidsram: from M0 to month 13
The safety will be assessed by the adverse events including serious adverse events collected during the study.
from M0 to month 13

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Composite criteria of the predicted humoral response at M20
Tidsram: 20 months

Predicted humoral vaccine response rate will be assessed by the predicted humoral vaccine response rates at M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).

Anti-VZV gE IgG at M20 will be assessed by the adjusted Geometric Mean Titers of anti-VZV gE IgG at M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The overall predicted humoral exposure from M0 to M20
Tidsram: 20 months
It will be assessed by the areas under the curve (AUC) of anti-VZV gE IgG titers between M0 and M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The predicted cellular response at M20
Tidsram: 20 months
It will be assessed by the predicted cellular vaccine rate response proportions of gE specific CD4[AIM+] T cells among CD4 T cells of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
The overall predicted cellular exposure from M0 to M20
Tidsram: 20 months
It will be assessed by the areas under the curve (AUC) of gE-specific CD4[AIM+] T cells among CD4 T cells between M0 and M20 of the M0-M6 RZV vaccine schedule ("6 months" group) and the M0-M2 RZV vaccine schedule ("2 months" group).
20 months
Composite criteria of the associated factors with early and persistent, humoral and cellular vaccine responses
Tidsram: 20 months
The factors which will be studied are : age, sex, number of prior anti-CD20 infusions, type of latest DMT before anti-CD20 therapy, albumin and gammaglobulin levels, Ig G levels, leukocyte counts, T and B cell immunophenotyping, and immune exhaustion and immunosenescence markers throughout the study.
20 months
The correlation between the titers of anti-VZV gE IgG by ELISA and the titers of total IgG anti-VZV by the commercial Diasorin serological test.
Tidsram: 20 months
It will be assessed by the correlation between ELISA gE titer and the total anti-VZV glycoproteins IgG measured by the Liaison XL® Diasorin serological test.
20 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

University Hospital, Toulouse

Utredare

  • Huvudutredare: Jonathan Ciron, MD, University Hospital, Toulouse

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

20 oktober 2026

Primärt slutförande (Beräknad)

20 juni 2030

Avslutad studie (Beräknad)

30 november 2030

Studieregistreringsdatum

Först inskickad

7 september 2026

Först inskickad som uppfyllde QC-kriterierna

7 september 2026

Första postat (Faktisk)

14 september 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

7 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • RC31/25/0535
  • 2025 (U.S.S. NIH-anslag/kontrakt: Faculty of Social Sciences Scientific Grant at the University of Gdańsk)
  • PHRC 24-0185 (Annat bidrag/finansieringsnummer: French Ministry of Health)
  • 2025-525106-37-00 (Annan identifierare: ID-RCB)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera